Vident Investment Advisory’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Vident Investment Advisory’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-320,492	Closed	-$1.41M	–	955
2018 Q3	$1.41M	Sell	320,492 -21,360	-6%	-$118K	0.06%	396
2018 Q2	$2.46M	Buy	+341,852	New	+$2.33M	0.1%	282
2017 Q2	–	Sell	-170,534	Closed	-$674K	–	456
2017 Q1	$674K	Buy	170,534 +28,420	+20%	+$143K	0.07%	328
2016 Q4	$696K	Buy	+142,114	New	+$854K	0.08%	314

Other funds holding SRNE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vident Investment Advisory's SRNE Position: Q4 2018 in Review

Vident Investment Advisory sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2018, closing a stake of 320,492 shares — an estimated $1.41M sold.

Vident Investment Advisory first reported a position in SRNE in Q4 2016 and held it in 4 quarters. The position peaked at $2.46M in Q2 2018. 78 funds tracked by Wall St. Rank hold SRNE as of Q4 2018.

Vident Investment Advisory reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
Vident Investment Advisory sold 320,492 Sorrento Therapeutics, Inc. shares in Q4 2018, an estimated $1.41M.
Vident Investment Advisory first reported a position in Sorrento Therapeutics, Inc. in Q4 2016 and held it in 4 quarters.
Vident Investment Advisory's Sorrento Therapeutics, Inc. position peaked at $2.46M in Q2 2018.
78 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2018.

Based on Vident Investment Advisory's 13F filing for Q4 2018, filed 14 Feb 2019.